Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia

Detalhes bibliográficos
Autor(a) principal: Louzã, Mário Rodrigues
Data de Publicação: 2011
Outros Autores: Elkis, Helio, Ruschel, Sandra, Oliveira, Irismar Reis de, Bressan, Rodrigo Affonseca, Abreu, Paulo Belmonte de, Grabowski, Hamilton, Appolinário, José Carlos
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UFBA
Texto Completo: http://www.repositorio.ufba.br/ri/handle/ri/5515
Resumo: texto completo: acesso restrito; p.391–398.
id UFBA-2_7b7fce514bcc87b2403a5772a5989317
oai_identifier_str oai:repositorio.ufba.br:ri/5515
network_acronym_str UFBA-2
network_name_str Repositório Institucional da UFBA
repository_id_str 1932
spelling Louzã, Mário RodriguesElkis, HelioRuschel, SandraOliveira, Irismar Reis deBressan, Rodrigo AffonsecaAbreu, Paulo Belmonte deGrabowski, HamiltonAppolinário, José CarlosLouzã, Mário RodriguesElkis, HelioRuschel, SandraOliveira, Irismar Reis deBressan, Rodrigo AffonsecaAbreu, Paulo Belmonte deGrabowski, HamiltonAppolinário, José Carlos2012-03-06T19:56:21Z20111178-2021http://www.repositorio.ufba.br/ri/handle/ri/5515v. 7.texto completo: acesso restrito; p.391–398.Background: Long-acting injectable antipsychotics may improve medication adherence, thereby improving overall treatment effectiveness. This study aimed to evaluate the effectiveness, safety, and tolerability of risperidone long-acting injection in schizophrenic patients switched from oral antipsychotic medication. Methods: In a 12-month, multicenter, open-label, noncomparative study, symptomatically stable patients on oral antipsychotic medication with poor treatment adherence during the previous 12 months received intramuscular injections of risperidone long-acting injection (25 mg starting dose) every 2 weeks. The primary endpoint was the change in Positive and Negative Syndrome Scale (PANSS) total score. Results: Of the 60 patients who were screened, 53 received at least one injection (safety population), and 51 provided at least one postbaseline assessment. Mean PANSS total scores improved significantly throughout the study and at endpoint. Significant improvements were also observed in Clinical Global Impression of Severity, Personal and Social Performance, and Drug Attitude Inventory scales. Risperidone long-acting injection was safe and well- tolerated. Severity of movement disorders on the Extrapyramidal Symptom Rating Scale was reduced significantly. The most frequently reported adverse events were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). Conclusion: Risperidone long-acting injection was associated with significant symptomatic improvements in stable patients with schizophrenia following a switch from previous antipsychotic medications.Submitted by Ana Valéria de Jesus Moura (anavaleria_131@hotmail.com) on 2012-03-06T19:56:21Z No. of bitstreams: 1 NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf: 205337 bytes, checksum: baebc6dbfffd4b121be24a2b22102c8f (MD5)Made available in DSpace on 2012-03-06T19:56:21Z (GMT). No. of bitstreams: 1 NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf: 205337 bytes, checksum: baebc6dbfffd4b121be24a2b22102c8f (MD5) Previous issue date: 2011http://dx.doi.org/10.2147/NDT.S20589reponame:Repositório Institucional da UFBAinstname:Universidade Federal da Bahia (UFBA)instacron:UFBApatient complianceadherencerisperidonedelayed-action preparationsschizophreniaLong-acting injectable risperidone in partially adherent and nonadherent patients with schizophreniaNeuropsychiatric Disease and Treatmentinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article10000-01-01enginfo:eu-repo/semantics/openAccessORIGINALNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfapplication/pdf205337https://repositorio.ufba.br/bitstream/ri/5515/1/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdfbaebc6dbfffd4b121be24a2b22102c8fMD51LICENSElicense.txtlicense.txttext/plain1762https://repositorio.ufba.br/bitstream/ri/5515/2/license.txt1b89a9a0548218172d7c829f87a0eab9MD52TEXTNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txtNDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txtExtracted texttext/plain36768https://repositorio.ufba.br/bitstream/ri/5515/3/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txt6008e0e8f91b5cd6d662099ecd1c2f3bMD53ri/55152022-07-05 14:02:49.301oai:repositorio.ufba.br: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Repositório InstitucionalPUBhttp://192.188.11.11:8080/oai/requestopendoar:19322022-07-05T17:02:49Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)false
dc.title.pt_BR.fl_str_mv Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
dc.title.alternative.pt_BR.fl_str_mv Neuropsychiatric Disease and Treatment
title Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
spellingShingle Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
Louzã, Mário Rodrigues
patient compliance
adherence
risperidone
delayed-action preparations
schizophrenia
title_short Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_full Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_fullStr Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_full_unstemmed Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
title_sort Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia
author Louzã, Mário Rodrigues
author_facet Louzã, Mário Rodrigues
Elkis, Helio
Ruschel, Sandra
Oliveira, Irismar Reis de
Bressan, Rodrigo Affonseca
Abreu, Paulo Belmonte de
Grabowski, Hamilton
Appolinário, José Carlos
author_role author
author2 Elkis, Helio
Ruschel, Sandra
Oliveira, Irismar Reis de
Bressan, Rodrigo Affonseca
Abreu, Paulo Belmonte de
Grabowski, Hamilton
Appolinário, José Carlos
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Louzã, Mário Rodrigues
Elkis, Helio
Ruschel, Sandra
Oliveira, Irismar Reis de
Bressan, Rodrigo Affonseca
Abreu, Paulo Belmonte de
Grabowski, Hamilton
Appolinário, José Carlos
Louzã, Mário Rodrigues
Elkis, Helio
Ruschel, Sandra
Oliveira, Irismar Reis de
Bressan, Rodrigo Affonseca
Abreu, Paulo Belmonte de
Grabowski, Hamilton
Appolinário, José Carlos
dc.subject.por.fl_str_mv patient compliance
adherence
risperidone
delayed-action preparations
schizophrenia
topic patient compliance
adherence
risperidone
delayed-action preparations
schizophrenia
description texto completo: acesso restrito; p.391–398.
publishDate 2011
dc.date.issued.fl_str_mv 2011
dc.date.accessioned.fl_str_mv 2012-03-06T19:56:21Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://www.repositorio.ufba.br/ri/handle/ri/5515
dc.identifier.issn.none.fl_str_mv 1178-2021
dc.identifier.number.pt_BR.fl_str_mv v. 7.
identifier_str_mv 1178-2021
v. 7.
url http://www.repositorio.ufba.br/ri/handle/ri/5515
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.source.pt_BR.fl_str_mv http://dx.doi.org/10.2147/NDT.S20589
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFBA
instname:Universidade Federal da Bahia (UFBA)
instacron:UFBA
instname_str Universidade Federal da Bahia (UFBA)
instacron_str UFBA
institution UFBA
reponame_str Repositório Institucional da UFBA
collection Repositório Institucional da UFBA
bitstream.url.fl_str_mv https://repositorio.ufba.br/bitstream/ri/5515/1/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf
https://repositorio.ufba.br/bitstream/ri/5515/2/license.txt
https://repositorio.ufba.br/bitstream/ri/5515/3/NDT-20589-long-acting-injectable-risperidone-in-partial-and-nonadheren_062211.pdf.txt
bitstream.checksum.fl_str_mv baebc6dbfffd4b121be24a2b22102c8f
1b89a9a0548218172d7c829f87a0eab9
6008e0e8f91b5cd6d662099ecd1c2f3b
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFBA - Universidade Federal da Bahia (UFBA)
repository.mail.fl_str_mv
_version_ 1801502441872556032

Registros relacionados